Quantcast

Latest Fludarabine Stories

2008-12-06 17:00:00

SAN FRANCISCO, Dec. 6 /PRNewswire-USNewswire/ -- Four studies highlighting late-breaking research advances in the treatment of cancer and sickle cell disease will be presented today at the 50th Annual Meeting of the American Society of Hematology in San Francisco, CA. Results from a study examining the ability of an investigational agent to improve endothelial dysfunction, a malfunction in the inner lining of blood vessels, in patients with sickle cell disease will be featured at a press...

2008-12-05 14:45:00

WAYNE, N.J., Dec. 5 /PRNewswire/ -- Bayer HealthCare Pharmaceuticals Inc. announced today that data on Campath(R) (alemtuzumab) and Leukine(R) (sargramostim) will be presented at the 50th Annual Meeting of the American Society of Hematology (ASH) from December 6-9, 2008 in San Francisco, California. Clinical investigators from leading oncology and hematology research centers will present data through several oral and poster presentations reporting important findings in leukemia-related...

2008-12-03 09:28:00

WHITE PLAINS, N.Y., Dec. 3 /PRNewswire/ -- The Leukemia & Lymphoma Society (LLS) and Memgen, LLC jointly announce the beginning of a new clinical trial of ISF35, a cancer vaccine, at the University of California, San Diego (UCSD). LLS is collaborating on this trial in the hopes that it will speed the development and approval of a novel approach aimed at treating patients with fludarabine refractory and/or 17p deleted chronic lymphocytic leukemia (CLL). Doctors at UCSD have already...

2008-10-08 12:00:38

Roche has announced that a Phase III study investigating MabThera in combination with chemotherapy has shown a significant improvement in progression free survival in patients with relapsed or refractory chronic lymphocytic leukemia. The pivotal REACH trial successfully met its primary endpoint by showing that patients treated with MabThera in combination with the current standard chemotherapy were able to significantly extend the amount of time they lived without their disease progressing,...

2008-10-07 09:00:55

Genentech and Biogen Idec have announced that a global Phase III study of Rituxan in combination with fludarabine and cyclophosphamide chemotherapy met its primary endpoint of improving progression-free survival, as assessed by investigators, in patients with previously treated CD20-positive chronic lymphocytic leukemia compared to chemotherapy alone. There were no new or unexpected safety signals reported in the study. An independent review of the primary endpoint is being conducted for US...

2008-10-07 03:00:08

Genentech, Inc. (NYSE:DNA) and Biogen Idec (Nasdaq:BIIB) today announced that a global Phase III study of Rituxan(R) (rituximab) in combination with fludarabine and cyclophosphamide chemotherapy met its primary endpoint of improving progression-free survival (PFS), as assessed by investigators, in patients with previously treated CD20-positive chronic lymphocytic leukemia (CLL) compared to chemotherapy alone. There were no new or unexpected safety signals reported in the study. An independent...

2008-08-12 03:00:18

By Anonymous United Kingdom - Bayer Schering Pharma AG and Genzyme Europe BV have informed physicians of six infectionrelated deaths, reported from a trial (CALGB10101) in which previously untreated, symptomatic B-cell chronic lymphocytic leukemia (CLL) patients were treated with fludarabine and rituximab followed by alemtuzumab for remission consolidation. Alemtuzumab (MabCampath(R)) is approved for the treatment of patients with B-cell chronic lymphocytic leukaemia (BCLL) for whom...

2008-07-31 12:01:05

COPENHAGEN, July 31 /PRNewswire-FirstCall/ -- Genmab A/S (OMX: GEN) and GlaxoSmithKline (LSE and NYSE: GSK) announced today positive top-line results from an interim analysis of the Phase III pivotal study evaluating ofatumumab (HuMax-CD20(R)) to treat two groups of chronic lymphocytic leukemia (CLL) patients with high unmet medical need. At the interim analysis, the study met the primary endpoint in both populations and the results from the secondary endpoints also support the primary...

2008-07-10 09:00:14

Genmab has completed recruitment of 56 patients in the Phase II study of ofatumumab in combination with fludarabine and cyclophosphamide to treat chronic lymphocytic leukemia in previously untreated patients. Patients in this open label study will be randomized into two treatment groups of 28 patients each. Each patient will receive six monthly infusions of either 500 or 1000mg of ofatumumab in combination with fludarabine and cyclophosphamide (FC). Disease status will be measured every...

2008-07-09 18:00:09

COPENHAGEN, Denmark, July 9 /PRNewswire-FirstCall/ -- Summary: Genmab has completed recruitment of patients in the Phase II study of ofatumumab in combination with fludarabine and cyclophosphamide to treat front line CLL. Genmab A/S (OMX: GEN) announced today it has completed recruitment of 56 patients in the Phase II study of ofatumumab (HuMax-CD20 (R)) in combination with fludarabine and cyclophosphamide (FC) to treat chronic lymphocytic leukemia (CLL) in previously untreated patients....


Word of the Day
monteith
  • A large punch-bowl of the eighteenth century, usually of silver and with a movable rim, and decorated with flutings and a scalloped edge. It was also used for cooling and carrying wine-glasses.
  • A kind of cotton handkerchief having white spots on a colored ground, the spots being produced by a chemical which discharges the color.
This word is possibly named after Monteith (Monteigh), 'an eccentric 17th-century Scotsman who wore a cloak scalloped at the hem.'
Related